Literature DB >> 28194646

Nanoemulsion Thermoreversible Pluronic F127-Based Hydrogel Containing Hyptis pectinata (Lamiaceae) Leaf Essential Oil Produced a Lasting Anti-hyperalgesic Effect in Chronic Noninflammatory Widespread Pain in Mice.

Lucindo J Quintans-Júnior1,2, Renan G Brito3,4, Jullyana S S Quintans3, Priscila L Santos3, Zaine T Camargo5, Péricles A Barreto5, Maria F Arrigoni-Blank6, Waldecy Lucca-Júnior7, Luciana Scotti8, Marcus T Scotti8, Sandra J Kolker4, Kathleen A Sluka4.   

Abstract

We evaluated if a nanostructured thermoreversible Pluronic F127-based hydrogel incorporated with Hyptis pectinata leaf essential oil (NE-EOH) produces a long-lasting anti-hyperalgesic effect on chronic muscle pain in an animal model. We induced chronic muscle pain by injecting the gastrocnemius with saline injections. Paw and muscle withdrawal thresholds and motor performance were evaluated after treatment and compared with morphine, diazepam, or vehicle. Naloxone and methysergide administration tested the involvement of opioid and serotonin receptors, respectively. Sites of action in the central nervous system for the NE-EOH were examined by measuring substance P (SP) levels in the spinal cord and Fos protein in the brainstem. NE-EOH increased paw and muscle withdrawal thresholds when compared with vehicle but had no effect on motor function. This analgesic effect was reversed by both naloxone and methysergide. NE-EOH decreased elevated substance P levels and reduced Fos-labeled neurons in the spinal cord and increased the number of Fos-labeled neurons in the periaqueductal gray (PAG), nucleus raphe magnus (NRM), and locus coeruleus (LC). NE-EOH was shown to produce a lasting anti-hyperalgesic effect. It uses opioid and serotonin receptors, activates brainstem inhibitory pathways, and reduces the release of excitatory neurotransmitters in the spinal cord and is a substance with potential to be used in the treatment of noninflammatory pain conditions. Graphical Abstract.

Entities:  

Keywords:  Hyperalgesia; Hyptis pectinata; Muscle; Opioid; Pain; Pluronic; Serotonin; Substance P

Mesh:

Substances:

Year:  2017        PMID: 28194646     DOI: 10.1007/s12035-017-0438-1

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  48 in total

1.  Antinociceptive effect of Hyptis pectinata leaves extracts.

Authors:  Ana C C D Lisboa; Iderjane C M Mello; Rogeria S Nunes; Marquês A Dos Santos; Angelo R Antoniolli; Rosilene M Marçal; Sócrates C de H Cavalcanti
Journal:  Fitoterapia       Date:  2006-07-06       Impact factor: 2.882

Review 2.  Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations.

Authors:  J J Escobar-Chávez; M López-Cervantes; A Naïk; Y N Kalia; D Quintanar-Guerrero; A Ganem-Quintanar
Journal:  J Pharm Pharm Sci       Date:  2006       Impact factor: 2.327

3.  Noxious cutaneous thermal stimuli induce a graded release of endogenous substance P in the spinal cord: imaging peptide action in vivo.

Authors:  B J Allen; S D Rogers; J R Ghilardi; P M Menning; M A Kuskowski; A I Basbaum; D A Simone; P W Mantyh
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

4.  Anatomical and physiological factors contributing to chronic muscle pain.

Authors:  Nicholas S Gregory; Kathleen A Sluka
Journal:  Curr Top Behav Neurosci       Date:  2014

Review 5.  Cyclodextrins: improving the therapeutic response of analgesic drugs: a patent review.

Authors:  Makson G B de Oliveira; Adriana G Guimarães; Adriano A S Araújo; Jullyana S S Quintans; Márcio R V Santos; Lucindo J Quintans-Júnior
Journal:  Expert Opin Ther Pat       Date:  2015-05-10       Impact factor: 6.674

Review 6.  Neuropathic pain in cancer.

Authors:  M T Fallon
Journal:  Br J Anaesth       Date:  2013-07       Impact factor: 9.166

7.  Characterization of a method for measuring primary hyperalgesia of deep somatic tissue.

Authors:  David A Skyba; Rajan Radhakrishnan; Kathleen A Sluka
Journal:  J Pain       Date:  2005-01       Impact factor: 5.820

8.  Differentiation of neuronal from non-neuronal Substance P.

Authors:  Nuray Erin; Ozkan Ulusoy
Journal:  Regul Pept       Date:  2008-10-25

9.  Improvement of p-cymene antinociceptive and anti-inflammatory effects by inclusion in β-cyclodextrin.

Authors:  Jullyana de Souza Siqueira Quintans; Paula Passos Menezes; Márcio Roberto Viana Santos; Leonardo Rigoldi Bonjardim; Jackson Roberto Guedes Silva Almeida; Daniel Pens Gelain; Adriano Antunes de Souza Araújo; Lucindo José Quintans-Júnior
Journal:  Phytomedicine       Date:  2013-01-26       Impact factor: 5.340

10.  Efficacy and safety of medicinal plants or related natural products for fibromyalgia: a systematic review.

Authors:  Simone de Souza Nascimento; Josimari Melo Desantana; Fernando Kenji Nampo; Eurica Adélia Nogueira Ribeiro; Daniel Lira da Silva; João Xavier Araújo-Júnior; Jackson Roberto Guedes da Silva Almeida; Leonardo Rigoldi Bonjardim; Adriano Antunes de Souza Araújo; Lucindo José Quintans-Júnior
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-04       Impact factor: 2.629

View more
  3 in total

Review 1.  Application Status of Sacrificial Biomaterials in 3D Bioprinting.

Authors:  Siyu Liu; Tianlin Wang; Shenglong Li; Xiaohong Wang
Journal:  Polymers (Basel)       Date:  2022-05-27       Impact factor: 4.967

Review 2.  Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update.

Authors:  Rosalba Siracusa; Rosanna Di Paola; Salvatore Cuzzocrea; Daniela Impellizzeri
Journal:  Int J Mol Sci       Date:  2021-04-09       Impact factor: 5.923

3.  Antinociceptive Activity of Chemical Components of Essential Oils That Involves Docking Studies: A Review.

Authors:  Davidson Barbosa Assis; Humberto de Carvalho Aragão Neto; Diogo Vilar da Fonsêca; Humberto Hugo Nunes de Andrade; Renan Marinho Braga; Nader Badr; Mayara Dos Santos Maia; Ricardo Dias Castro; Luciana Scotti; Marcus Tullius Scotti; Reinaldo Nóbrega de Almeida
Journal:  Front Pharmacol       Date:  2020-05-29       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.